SYDNEY (Reuters) -China’s Giant Biogene has raised about $301 million in a Hong Kong top up placement, according to a term sheet seen by Reuters.
The company sold 35 million shares at HK$66.65, a 9.5% discount to Giant Biogene’s closing price on the Hong Kong Stock Exchange on Wednesday, the term sheet showed. The final price was at the bottom end of the price range flagged to investors when the deal launched.
(Reporting by Scott Murdoch; Editing by Leslie Adler)
